TVM
VRTX icon

True Vision MN’s Vertex Pharmaceuticals VRTX Stock Holding History

True Vision MN’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-943
Closed -$439K – 116
2024
Q3 		$439K Sell
943
-101
-10% -$48.5K 0.26% 71
2024
Q2 		$489K Buy
1,044
+2
+0.2% +$868 0.32% 59
2024
Q1 		$414K Buy
1,042
+110
+12% +$46.5K 0.29% 67
2023
Q4 		$379K Buy
+932
New +$344K 0.3% 73

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

True Vision MN's VRTX Position: Q4 2024 in Review

True Vision MN sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 943 shares — an estimated $439K sold.

True Vision MN first reported a position in VRTX in Q4 2023 and held it in 4 quarters. The position peaked at $489K in Q2 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • True Vision MN reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • True Vision MN sold 943 Vertex Pharmaceuticals shares in Q4 2024, an estimated $439K.
  • True Vision MN first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • True Vision MN's Vertex Pharmaceuticals position peaked at $489K in Q2 2024.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on True Vision MN's 13F filing for Q4 2024, filed 29 Jan 2025.